Ischemic heart disease
Conditions
Interventions
From administration of the atorvastatin(10mg/day) and ezetimibe(10mg/day) to follow up coronary arteriography by PCI(after 6-9 months). Blood sampling is performed before PCI and after PCI at day 1
Sponsors
Heart/vascular internal medicine,fukuoka university
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The subjects include the patients who did not receive statin before coronary stent implantation and are successfully implanted with a stent at Fukuoka University Hospital.
Exclusion criteria
Exclusion criteria: Patients with familial hyperlipidaemia, a severe liver dysfunction (AST / ALT more than the double of the reference value), severe renal dysfunction (Cr more than 2mg/dl), diabetes mellitus inadequate control (HbA1c more than 7mg/dl), the possibility of pregnancy, and a history of hypersensitivity for the ingredient of the study drug are excluded from the study.The patients who fall under the contraindication of the study drug and the inappropriate patients by doctor's judgement are also excluded.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Plaque volume by IVUS, Plaque area by MSCT, LV blood flow by the contrast echocardiography, the plaque by the carotid echo, a vascular endothelium function by FMD, the evaluation of the change of ,adhesion molecule. The measurement of blood levels of chemokine, MMP(Matrix Metalloproteinase), TIMP(Tissue Inhibitor of Metalloproteinase), adiponectine. Major adverse cardiac events (MACE) and target lesion revascularization (TLR) during follow up. | — |
Primary
| Measure | Time frame |
|---|---|
| Evaluation of %DS by QCA(6-9 months after PCI) %DS:percent diameter stenosis QCA:quantitative coronary angiography | — |
Countries
Japan
Contacts
Public ContactTadaaki Arimura,Makoto sugihara
Fukuoka University Hospital Circulatory organ internal medicine
Outcome results
None listed